2021年国药集团一致药业股份有限公司年报

China National Accord Medicines Corporation Ltd. Annual Report 2021 March 2022 Section I. Important Notice, Contents and Interpretation Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents. Lin Zhaoxiong, Principal of the Company, Gu Guolin, person in charger of accounting works and Wang Ying, person in charge of accounting organ (accounting principal) hereby confirm that the Financial Report of 2021 Annual Report is authentic, accurate and complete. All directors are attended the Board Meeting for report deliberation. The profit distribution plan that deliberated and approved by the Board is: based on total stock issued 428,126,983 shares, distributed 6.00Yuan (tax included) bonus in cash for every 10-share hold by all shareholders, 0 shares bonus issued (tax included) and no capitalizing of common reserves carried out. Contents Sction I Important Notice, Contents and Interpretation......1 Section II Company Profile and Main Financial Indexes......5 Section III Management Discussion and Analysis......10 Section IV Corporate Governance......错误！未定义书签。 Section V Enviornmental and Social Responsibility......错误！未定义书签。 Section VI Important Events ......83 Section VII Changes in shares and particular about shareholders......错误！未定义书签。9 Section VIII Preferred Stock......错误！未定义书签。9 Section IX Bonds......错误！未定义书签。0 Section X Financial Report......错误！未定义书签。1 DocumentsAvailable for Reference I.The financial statements carried with the signature and seals of the person in charge of the Company, person in charger of accounting works and person in charge of accounting organ(accounting supervisor); II.The original audit report bearing the seal of accounting firm and the original audit report signed and seal by the CPA; III.Original text of all documents of the Company as well as the manuscript of the announcement disclosed on the website designated by CSRC. Interpretation Items Refers to Contents Listed Company, Company, the Company, Refers to China National Accord Medicines Corporation Ltd. Sinopharm Accord, the Group SINOPHARM Refers to China National Pharmaceutical Group Corporation Sinopharm Holding Refers to Sinopharm Group Co., Ltd, Controlling shareholder of the Company Company Law Refers to Company Law of the People’s Republic of China Securities Law Refers to Securities Law of the People’s Republic of China Yuan, 10 thousand Yuan, 100 million Yuan Refers to RMB, RMB 10 thousand, RMB 100 million Terminology: Refers to SPD hospital logistics supply chain extension business, IVD 4D business Refers to diagnostic reagent business, CSSD disinfection service, and MWD equipment life cycle management business GPO Refers to Group purchasing organizations Abbreviation: Refers to Sinopharm Holding Guangzhou Refers to Sinopharm Holding Guangzhou Co., Ltd. Guoda Drugstore Refers to Sinopharm Holding Guoda Drugstore Co., Ltd. Sinopharm Holding Guangxi Refers to Sinopharm Holding Guangxi Co., Ltd. China National Zhijun Refers to China National Zhijun (Shenzhen) Pharmaceutical Co., Ltd. Zhijun Pharmacy Trade Refers to Shenzhen Zhijun Pharmacy Trade Co., Ltd. Zhijun Pingshan Refers to China National Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. Main Luck Pharmaceuticals Refers to Shenzhen Main Luck Pharmaceuticals Inc. Section II Company Profile and Main Financial Indexes I. Company information Short form of the stock Sinopharm Accord, Accord B Stock code 000028, 200028 Stock exchange for listing Shenzhen Stock Exchange Name of the Company (in 国药集团一致药业股份有限公司 Chinese) Short form of the Company 国药一致 (in Chinese) Foreign name of the Company China NationalAccord Medicines Corporation Ltd. (if applicable) Short form of foreign name of SinopharmAccord the Company (if applicable) Legal representative Lin Zhaoxiong Registrations add. Accord Pharm. Bldg , No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province Code for registrations add 518029 Historical changes in the No changes registration address Offices add. Accord Pharm. Bldg, No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province Codes for office add. 518029 Company’s Internet Web Site http://www.szaccord.com.cn E-mail gyyz0028@sinopharm.com II. Person/Way to contact Secretary of the Board Securities affairs representative Name Chen Changbing Wang Zhaoyu Accord Pharm. Bldg., No. 15, Ba Gua Si Accord Pharm. Bldg., No. 15, Ba Gua Si Contact add. Road, Futian District, Shenzhen, Road, Futian District, Shenzhen, Guangdong Province Guangdong Province Tel. +(86)755 25875222 +(86)755 25875222 Fax. +(86)755 25195435 +(86)755 25195435 E-mail gyyzinvestor@sinopharm.com gyyz0028@sinopharm.com III. Information disclosure and preparation place Website of the Stock Exchange where the annual Securities Times, China Securities Journal, Hong Kong Commercial Daily report of the Company disclosed Media and Website where the annual report of the http://www.szse.cn ; http://www.cninfo.com.cn Company disclosed Preparation place for annual report Secretariat of the Board of Directors IV. Registration changes of the Company Organization code 91440300192186267U Changes of main business since listing (if No change. applicable) Previous changes for controlling No change. shareholders (if applicable) V. Other relevant information CPA engaged by the Company Name of CPA Ernst & Young CPA(Special General partnership) Offices add. for CPA 21/F, China Resources Building, No. 5001, Shennan East Road, Luohu District, Shenzhen Signing accountant Deng Dongmei, Li Yuanfeng Sponsor engaged by the Company for performing continuous supervision duties in reporting period □ Applicable √ Not applicable Financial consultant engaged by the Company for performing continuous supervision duties in reporting period □ Applicable √ Not applicable VI. Main accounting data and financial indexes Whether it has retroactive adjustment or re-statement on previous accounting data □ Yes √No Changes in the current 2021 2020 year over the previous 2019 year (+,-) Operating revenue (RMB) 68,357,809,571.99 59,649,455,012.03 14.60% 52,786,807,476.28 Net profit attributable to shareholders of the listed Company 1,336,427,752.22 1,401,892,593.23 -4.67% 1,267,931,291.32 (RMB)(Note 1) Net profit attributable to shareholders of the listed Company 1,286,305,975.28 1,369,652,035.50 -6.09% 1,226,765,271.97 after deducting non-recurring gains and losses (RMB) Net cash flow arising from 1,655,180,976.87 1,502,746,598.47 10.14% 2,012,653,189.74 operating activities (RMB) Basic earnings per share 3.12 3.27 -4.59% 2.96 (RMB/Share) (Note 1) Diluted earnings per share 3.12 3.27 -4.59% 2.96 (RMB/Share) Weighted average ROE 1.20 percentage points (Note 1) 9.29% 10.49% down 10.31% Changes at end of the Year-end of 2021 Year-end of 2020 current year compared Year-end of 2019 with the end of previous year (+,-) Total assets (RMB) 42,783,682,431.81 39,594,533,471.65 8.05% 34,028,843,214.20 Net assets attributable to shareholder of listed company 14,924,938,052.50 13,948,322,652.33 7.00% 12,911,140,435.88 (RMB) Note 1: Net profit attributable to shareholders of the listed Company has 4.67% declined from a year earlier, basic EPS drop 4.59% correspondingly, weighted average ROE decreased by 1.20 percentage points, mainly because according to the results of impairment tests on goodwill and intangible assets for the year, follow the principle of prudence, the goodwill and intangible assets (brand rights and sales network) from subordinate subsidiary- Shanghai Dingqun Enterprise Management Consulting Co., Ltd (and the Sinopharm H